Renaissance Technologies LLC Purchases 242,103 Shares of Taysha Gene Therapies, Inc. $TSHA

Renaissance Technologies LLC raised its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 141.5% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 413,203 shares of the company’s stock after acquiring an additional 242,103 shares during the quarter. Renaissance Technologies LLC owned approximately 0.14% of Taysha Gene Therapies worth $1,847,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in TSHA. Sei Investments Co. increased its position in shares of Taysha Gene Therapies by 7.6% in the first quarter. Sei Investments Co. now owns 51,472 shares of the company’s stock valued at $230,000 after acquiring an additional 3,614 shares during the last quarter. Cetera Investment Advisers boosted its position in Taysha Gene Therapies by 34.5% during the first quarter. Cetera Investment Advisers now owns 28,450 shares of the company’s stock valued at $127,000 after purchasing an additional 7,296 shares during the last quarter. Militia Capital Management LLC bought a new position in Taysha Gene Therapies in the first quarter valued at approximately $208,000. Principal Financial Group Inc. grew its stake in Taysha Gene Therapies by 26.2% in the first quarter. Principal Financial Group Inc. now owns 16,185 shares of the company’s stock valued at $72,000 after purchasing an additional 3,362 shares in the last quarter. Finally, Chicago Partners Investment Group LLC increased its position in shares of Taysha Gene Therapies by 2.5% during the 1st quarter. Chicago Partners Investment Group LLC now owns 170,751 shares of the company’s stock worth $763,000 after purchasing an additional 4,210 shares during the last quarter. Institutional investors own 77.70% of the company’s stock.

Insider Buying and Selling at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $6.24, for a total transaction of $1,248,000.00. Following the transaction, the insider owned 936,410 shares in the company, valued at approximately $5,843,198.40. This trade represents a 17.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.48% of the company’s stock.

Taysha Gene Therapies Stock Up 4.9%

Shares of TSHA opened at $6.68 on Wednesday. Taysha Gene Therapies, Inc. has a 52 week low of $2.69 and a 52 week high of $7.30. The firm has a market cap of $1.92 billion, a P/E ratio of -17.58 and a beta of 1.22. The firm’s 50-day simple moving average is $6.08 and its 200 day simple moving average is $5.47. The company has a debt-to-equity ratio of 0.23, a quick ratio of 14.04 and a current ratio of 14.04.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, analysts forecast that Taysha Gene Therapies, Inc. will post -0.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on TSHA. Citigroup reiterated an “outperform” rating on shares of Taysha Gene Therapies in a research note on Tuesday, June 23rd. Wall Street Zen downgraded shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Pivotal Research set a $14.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, June 23rd. BMO Capital Markets increased their price target on shares of Taysha Gene Therapies from $10.00 to $14.00 and gave the company an “outperform” rating in a research note on Tuesday, June 23rd. Finally, Bank of America lifted their price objective on shares of Taysha Gene Therapies from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, June 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $12.77.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.